Syncom Formulations (India) Limited (SYNCOMF.BO)
INR 21.07
(0.0%)
INR 21.07
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 724.86 Million INR | -12.86% |
| 2022 | 831.81 Million INR | 43.94% |
| 2021 | 577.9 Million INR | -6.92% |
| 2020 | 620.9 Million INR | 2791.17% |
| 2019 | 21.47 Million INR | -75.24% |
| 2018 | 86.74 Million INR | -30.3% |
| 2017 | 124.46 Million INR | -0.04% |
| 2016 | 124.51 Million INR | 121.48% |
| 2015 | 56.21 Million INR | -7.49% |
| 2014 | 60.77 Million INR | 83.95% |
| 2013 | 33.03 Million INR | 60.89% |
| 2012 | 20.53 Million INR | 42.1% |
| 2011 | 14.45 Million INR | -26.93% |
| 2010 | 19.77 Million INR | -79.19% |
| 2009 | 95.01 Million INR | -11.56% |
| 2008 | 107.43 Million INR | 48.64% |
| 2007 | 72.28 Million INR | 2.68% |
| 2006 | 70.39 Million INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 724.86 Million INR | 0.0% |
| 2023 Q2 | 800.89 Million INR | 0.0% |
| 2023 FY | 724.86 Million INR | -12.86% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q2 | 957.6 Million INR | 0.0% |
| 2022 FY | 831.81 Million INR | 43.94% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 831.81 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 FY | 577.9 Million INR | -6.92% |
| 2021 Q4 | 577.9 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 643.65 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q4 | 620.9 Million INR | 0.0% |
| 2020 FY | 620.9 Million INR | 2791.17% |
| 2020 Q2 | 67.62 Million INR | 0.0% |
| 2019 Q4 | 21.47 Million INR | 0.0% |
| 2019 Q2 | 88.05 Million INR | 0.0% |
| 2019 FY | 21.47 Million INR | -75.24% |
| 2018 Q4 | 86.74 Million INR | 0.0% |
| 2018 FY | 86.74 Million INR | -30.3% |
| 2018 Q2 | 73.42 Million INR | 0.0% |
| 2017 Q4 | 124.46 Million INR | 0.0% |
| 2017 FY | 124.46 Million INR | -0.04% |
| 2016 FY | 124.51 Million INR | 121.48% |
| 2016 Q4 | 124.51 Million INR | 0.0% |
| 2015 Q2 | 32.28 Million INR | 0.0% |
| 2015 Q4 | 56.21 Million INR | 0.0% |
| 2015 FY | 56.21 Million INR | -7.49% |
| 2014 Q2 | 90.67 Million INR | 0.0% |
| 2014 Q4 | 60.77 Million INR | 0.0% |
| 2014 FY | 60.77 Million INR | 83.95% |
| 2013 Q2 | 37.99 Million INR | 0.0% |
| 2013 Q4 | 33.03 Million INR | 0.0% |
| 2013 FY | 33.03 Million INR | 60.89% |
| 2012 FY | 20.53 Million INR | 42.1% |
| 2012 Q4 | 20.53 Million INR | 0.0% |
| 2012 Q2 | 28.4 Million INR | 0.0% |
| 2011 FY | 14.45 Million INR | -26.93% |
| 2010 FY | 19.77 Million INR | -79.19% |
| 2009 FY | 95.01 Million INR | -11.56% |
| 2008 FY | 107.43 Million INR | 48.64% |
| 2007 FY | 72.28 Million INR | 2.68% |
| 2006 FY | 70.39 Million INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | 352.8 Million INR | -105.461% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -4094.098% |
| Sigachi Industries Limited | 1.43 Billion INR | 49.328% |
| Bal Pharma Limited | 1.39 Billion INR | 48.093% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -336.099% |
| Medico Remedies Limited | 80.5 Million INR | -800.41% |
| Lasa Supergenerics Limited | 220.76 Million INR | -228.347% |
| Venus Remedies Limited | 413.3 Million INR | -75.385% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | -18.539% |
| Alpa Laboratories Limited | 52.46 Million INR | -1281.618% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 88.594% |
| Shilpa Medicare Limited | 9.37 Billion INR | 92.267% |
| Aarti Drugs Limited | 5.64 Billion INR | 87.154% |
| Lupin Limited | 29.21 Billion INR | 97.519% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 98.91% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 90.986% |
| Windlas Biotech Limited | 36.41 Million INR | -1890.843% |
| Suven Life Sciences Limited | 7.09 Million INR | -10113.696% |
| Eris Lifesciences Limited | 27.81 Billion INR | 97.394% |
| Valiant Laboratories Limited | 767.08 Million INR | 5.504% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 80.806% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 92.834% |
| Ipca Laboratories Limited | 14.38 Billion INR | 94.96% |
| Bliss GVS Pharma Limited | 998.4 Million INR | 27.397% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 97.786% |
| Bajaj HealthCare Limited | 3.32 Billion INR | 78.221% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Mankind Pharma Limited | 2.07 Billion INR | 65.011% |
| Laurus Labs Limited | 25.77 Billion INR | 97.188% |
| Piramal Pharma Limited | 47.1 Billion INR | 98.461% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 98.198% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 85.874% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 94.111% |
| Unichem Laboratories Limited | 2.47 Billion INR | 70.714% |
| Sequent Scientific Limited | 4.87 Billion INR | 85.137% |
| Novartis India Limited | 69.7 Million INR | -939.98% |
| Wanbury Limited | 1.16 Billion INR | 37.772% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | -11.524% |
| Wockhardt Limited | 23.56 Billion INR | 96.923% |
| Themis Medicare Limited | 957.92 Million INR | 24.329% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -710.721% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 98.022% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -322.712% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 96.379% |
| Divi's Laboratories Limited | 30 Million INR | -2316.22% |
| NATCO Pharma Limited | 3.71 Billion INR | 80.472% |
| Gufic Biosciences Limited | 3.32 Billion INR | 78.227% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -121.266% |
| Ind-Swift Limited | 10.13 Billion INR | 92.851% |
| Procter & Gamble Health Limited | 95.6 Million INR | -658.228% |
| FDC Limited | 205.18 Million INR | -253.274% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 62.526% |
| Granules India Limited | 13.15 Billion INR | 94.488% |
| Medicamen Biotech Limited | 308.17 Million INR | -135.215% |
| Alkem Laboratories Limited | 14.18 Billion INR | 94.89% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -1476.413% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -16415.516% |
| Brooks Laboratories Limited | 56.41 Million INR | -1184.791% |
| Megasoft Limited | 1.47 Billion INR | 50.705% |
| ZIM Laboratories Limited | 1.08 Billion INR | 33.391% |
| Strides Pharma Science Limited | 25.16 Billion INR | 97.12% |
| Neuland Laboratories Limited | 953.89 Million INR | 24.01% |
| Morepen Laboratories Limited | 289.99 Million INR | -149.961% |
| Hikal Limited | 8.17 Billion INR | 91.134% |
| Indoco Remedies Limited | 6.71 Billion INR | 89.213% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | 74.588% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -129.051% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | 26.404% |
| Hester Biosciences Limited | 2.44 Billion INR | 70.338% |